- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Bilastine and Montelukast combo safe and effective for Allergic Rhinitis patients
![Bilastine and Montelukast combo safe and effective for Allergic Rhinitis patients Bilastine and Montelukast combo safe and effective for Allergic Rhinitis patients](https://medicaldialogues.in/h-upload/2023/05/19/750x450_210089-untitled-design-49.webp)
India: A study published in the Journal of Asthma by Shubhadeep D Sinha and the team has provided information on the excellent tolerability of a combo of Bilastine 20mg and Montelukast 10mg in patients with Allergic rhinitis.
Explaining research background, they said that in AR, Histamine and cysteinyl leukotrienes (CysLTs) are potent inflammatory mediators. Additional benefits can be obtained using combination therapy against these potent inflammatory mediators.
Previous researchers have mentioned that using Levocetirizine and highly selective leukotriene receptor antagonists like Montelukast are widely prescribed in combination due to the additional benefits of this combination in AR patients.
The Indian study evaluated the efficacy and safety of Bilastine 20mg and Montelukast 10mg fixed drug combination at 16 ENT centres.
Important study points are:
- The study included Adult patients with AR for at least one year with positive IgE antibody test and 12-hour NSS score > 36 during the last three days.
- The patients were randomized to receive either a fixed-dose combination or FDC of Bilastine 20 mg & Montelukast 10 mg or FDC Montelukast 10 mg & Levocetirizine 5 mg tablets for four weeks.
- The primary endpoints measured was change in mean total symptom score (nasal symptom scores (NSS) & non-nasal symptom scores (NNSS)) (baseline to week 4).
- The change in mean TSS was 16.6 units in Bilastine 20mg and Montelukast 10mg FDC compared to 17 units in Levocetirizine 5mg and Montelukast 10mg FDC.
- There was a comparable difference in mean change between groups.
The study addressed the combination of Bilastine 20mg and Montelukast 10mg in allergic rhinitis patients.
They also said that the combination was well tolerated in such patients
Further reading:
Sinha SD, Perapogu S, Chary SS, Ramesh H, Bakshi J, Singh A, Ahmed AK, Mohan Reddy B, Panapakam M, Talluri L, Vattipalli R. Efficacy and Safety of Fixed-Dose Combination of Bilastine in Adult Patients with Allergic Rhinitis: A Phase III, Randomized, Multi-Center, Double-Blind, Active Controlled Clinical Study. J Asthma. 2023 May 4:1-9. doi: 10.1080/02770903.2023.2209175.
BDS, MDS in Periodontics and Implantology
Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751